MedTrace Logo

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

NCT04983550 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2021-07-30

No results posted yet for this study

Summary

This study is a multicenter, randomized, controlled, open-label, phase II study to evaluate the efficacy and safety of SG001 in combination with doxorubicin hydrochloride liposome injection in patients with platinum-resistant relapsed epithelial ovarian cancer.

Conditions

Interventions

DRUG

SG001

Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w

DRUG

Doxorubicin hydrochloride liposome injection

Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2023-01-31
Completion
2024-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04983550 on ClinicalTrials.gov